Loading fund overlap…
20 of 20 unique stocks in common · Jaccard: 100%
A weighted portfolio overlap of 97.58% indicates a extreme overlap (near-identical portfolios). This means that out of every ₹100 you invest across these two schemes, approximately ₹97.58 is allocated to the exact same companies at the same relative proportions. The schemes share 20 common holdings.
The largest overlapping asset in their portfolios is Sun Pharmaceutical Industries, which commands a weight of 19.05% in Aditya Birla Sun Life Nifty Healthcare ETF and 18.37% in ICICI Prudential Nifty Healthcare ETF. Holding both schemes increases your concentration in Sun Pharmaceutical Industries rather than expanding your diversification.
If the overlap is above 30%, it is typically because both schemes benchmark to the same index (e.g. Nifty 50 or Nifty LargeMidcap 250) or overlap in their top large-cap picks. To improve your portfolio's diversification, consider allocating one of these tranches to a category with lower structural correlation (such as a mid-cap, small-cap, or international equity fund).
| Stock | in Aditya | in ICICI |
|---|---|---|
| Sun Pharmaceutical IndustriesPharmaceuticals & Biotechnology | 19.05% | 18.37% |
| Divi's LaboratoriesPharmaceuticals & Biotechnology | 8.22% | 8.17% |
| Apollo Hospitals EnterpriseHealthcare Services | 7.82% | 8.11% |
| Dr. Reddy's LaboratoriesPharmaceuticals & Biotechnology | 8.02% | 7.66% |
| CiplaPharmaceuticals & Biotechnology | 7.33% | 7.60% |
| Max Healthcare InstituteHealthcare Services | 7.35% | 6.92% |
| LupinPharmaceuticals & Biotechnology | 5.56% | 5.30% |
| Fortis HealthcareHealthcare Services | 4.79% | 4.67% |
| Torrent PharmaceuticalsPharmaceuticals & Biotechnology | 4.36% | 4.45% |
| Laurus LabsPharmaceuticals & Biotechnology | 4.26% | 5.11% |
| Aurobindo PharmaPharmaceuticals & Biotechnology | 3.86% | 3.85% |
| Glenmark PharmaceuticalsPharmaceuticals & Biotechnology | 3.60% | 3.30% |
| Alkem LaboratoriesPharmaceuticals & Biotechnology | 3.14% | 3.10% |
| BioconPharmaceuticals & Biotechnology | 2.55% | 2.95% |
| Mankind PharmaPharmaceuticals & Biotechnology | 2.53% | 2.59% |
| Zydus LifesciencesPharmaceuticals & Biotechnology | 2.22% | 2.60% |
| IPCA LaboratoriesPharmaceuticals & Biotechnology | 2.12% | 2.04% |
| Abbott IndiaPharmaceuticals & Biotechnology | 1.32% | 1.35% |
| Piramal PharmaPharmaceuticals & Biotechnology | 1.00% | 1.03% |
| Syngene InternationalHealthcare Services | 0.88% | 0.81% |
Weighted overlap = Σ min(weight in fund A, weight in fund B) across shared stocks, from each fund's latest public monthly portfolio (as on May 2026). Equity holdings only, ISIN-verified. Not investment advice.